Article Text

This article has a correction. Please see:

PDF
Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma
  1. A Russell-Swetek1,
  2. A N West2,
  3. J E Mintern3,
  4. J Jenkins4,
  5. C Rodriguez-Galindo5,
  6. R Ribeiro5,6,
  7. G P Zambetti1
  1. 1
    Department of Biochemistry, St Jude Children’s Research Hospital, Memphis, Tennessee, USA
  2. 2
    Interdisciplinary Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA
  3. 3
    Division of Oncology and Neuro-Oncology, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
  4. 4
    Department of Pathology, St Jude Children’s Research Hospital, Memphis, Tennessee, USA
  5. 5
    Department of Oncology, St Jude Children’s Research Hospital, Memphis, Tennessee, USA
  6. 6
    International Outreach Program, St Jude Children’s Research Hospital, Memphis, Tennessee, USA
  1. Dr G P Zambetti, Department of Biochemistry, St Jude Children’s Research Hospital, 332 N Lauderdale, Memphis TN 38105, USA; gerard.zambetti{at}stjude.org

Abstract

Paediatric choroid plexus carcinomas (CPC) and adrenocortical carcinomas (ACC) are exceedingly rare tumours, each occurring at an annual rate of 0.3 cases per million children or less. Although both tumour types are associated with Li–Fraumeni syndrome (LFS), the penetrance of germline TP53 mutations in CPC remains to be established. We report here a young boy without a family history of cancer who presented with CPC and subsequently ACC. Genetic testing revealed a novel de novo germline TP53 mutation (E285V). Neither tumour underwent loss of heterozygosity. Consistent with this observation, functional analyses demonstrated that E285V acts as a dominant negative mutant that is defective in regulating target gene expression, growth suppression and apoptosis. These results further strengthen the association between germline TP53 mutations and childhood CPC, even when occurring in the absence of familial tumour susceptibility.

Statistics from Altmetric.com

Footnotes

  • Funding: This study was funded by grants from the NIH/NCI CA63230 (GPZ), Cancer Center CORE Grant CA21765, and by the American Lebanese Syrian Associated Charities (ALSAC).

  • Competing interests: None.

  • Patient consent: Obtained.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Correction
    BMJ Publishing Group Ltd